173 related articles for article (PubMed ID: 38229838)
1. Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer.
Lee D; Lee J; Park H; Lee YJ; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Gland Surg; 2023 Dec; 12(12):1696-1704. PubMed ID: 38229838
[TBL] [Abstract][Full Text] [Related]
2. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
4. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
5. A Retrospective Clinical Analysis of Hyperthermic Intraperitoneal Chemotherapy in Gynecological Cancers: Technical Details, Tolerability, and Efficacy.
Minareci Y; Tosun OA; Sozen H; Topuz S; Salihoglu MY
Medeni Med J; 2020; 35(3):202-211. PubMed ID: 33110672
[TBL] [Abstract][Full Text] [Related]
6. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer.
Chen WC; Huang HJ; Yang LY; Pan YB; Huang KG; Lin CT; Chen MY; Tang YH; Chang TC; Lai CH; Chou HH
Biomed J; 2022 Oct; 45(5):821-827. PubMed ID: 34656802
[TBL] [Abstract][Full Text] [Related]
8. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma.
Lopez-Ramirez F; Sardi A; Studeman K; King MC; Falla-Zuniga LF; Nikiforchin A; Baron E; Nieroda C; Gushchin V; Diaz-Montes T
Eur J Surg Oncol; 2023 Aug; 49(8):1495-1503. PubMed ID: 37068984
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
[TBL] [Abstract][Full Text] [Related]
11. Survival and complications of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with intra-abdominal malignancies: A meta-analysis of randomized controlled trials.
Jian C; Mou H; Zhang Y; Fan Q; Ou Y
Front Pharmacol; 2023; 14():1094834. PubMed ID: 36969856
[No Abstract] [Full Text] [Related]
12. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
[TBL] [Abstract][Full Text] [Related]
14. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
15. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
Falla-Zuniga LF; Sardi A; King MC; Lopez-Ramirez F; Barakat P; Nieroda C; Diaz-Montes T; Gushchin V
Pleura Peritoneum; 2024 Mar; 9(1):15-22. PubMed ID: 38558871
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy.
Bhatt A; Glehen O
Visc Med; 2022 Apr; 38(2):109-119. PubMed ID: 35614893
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
19. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
[TBL] [Abstract][Full Text] [Related]
20. Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS.
Acs M; Gerken M; Schmitt V; Piso P; Königsrainer A; Baransi S; Yurttas C; Häusler S; Horvath P
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
